Skip to main navigation

close search window

CING | Nasdaq Listed

Header Menu

Company
Pipeline
Partners
Investors
Careers
Press Releases
Cingulate In the News
Contact us

Header Social TwitterLinkedInFacebookYoutube

Header Menu

Company
Pipeline
Partners
Investors
Careers
Press Releases
Cingulate In the News
Contact us

close search window

Search:

search submit button

A man and woman talking

Events & Presentations

Events & Presentations

Presentations

2025 AACAP Presentation 641.4 KB

2026 APSARD Poster 686.2 KB

CINGULATE NMA 2025 Poster 1.5 MB

LD Micro Main Event XVI Presentation

CTx-1301 Psych Congress Presentation 2023 846.1 KB

Past Presentations

CTx-2103 Psych Congress Presentation 2022

2017 AAPS Poster

2018 APSARD Poster

2020 AACAP Poster

2021 APSARD Poster

CTx-1301 Psych Congress Presentation 2023

Events

24 Jul 2025

Cingulate CEO Shane Schaffer Previews ADHD Documentary and more on the Big Biz Show

Click here for webcast

16 Jun 2025

Major Operational Updates from Cingulate’s CEO and CMO

Click here for webcast

29 May 2025

Cingulate's Indegene Commercialization Agreement

Click here for webcast

27 May 2025

What does an ADHD diagnosis mean to you?

Click here for webcast

22 May 2025

Pediatric Trial Shows Efficacy for CTx-1301

Click here for webcast

14 May 2025

Business Development and Licensing joins our CEO to discuss Cingulate's strategic roadmap

Click here for webcast

07 May 2025

How Did Cingulate Begin? CEO Shane Schaffer Shares the Story

Click here for webcast

07 Apr 2025

Big Biz Show Joins Cingulate at 37th Annual Roth Capital Conference

Click here for webcast

10 Mar 2025

CTx-1301 – Once Daily Entire Active Day Coverage

Click here for webcast

18 Feb 2025

Cingulate’s Shane Schaffer Discusses Commercialization Plans for CTx-1301

Click here for webcast

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

TwitterLinkedInFacebookYoutube

Contact us

1901 W 47th Place
Kansas City 66205

info@cingulate.com
913-942-2300

© Cingulate^® | PRIVACY POLICY